<DOC>
	<DOCNO>NCT02878603</DOCNO>
	<brief_summary>The objective study evaluate long-term safety efficacy caplacizumab , evaluate safety efficacy repeat use caplacizumab characterize long term impact TTP .</brief_summary>
	<brief_title>Follow-up Study Patients Who Completed Study ALX0681-C301 ( Post-HERCULES )</brief_title>
	<detailed_description />
	<mesh_term>Purpura , Thrombocytopenic</mesh_term>
	<mesh_term>Purpura</mesh_term>
	<mesh_term>Purpura , Thrombotic Thrombocytopenic</mesh_term>
	<criteria>1 . Completed Final ( 28 day ) FU visit Study ALX0681C301 . 2 . Is â‰¥18 year age time sign informed consent form ( ICF ) . 3 . Provided informed consent prior initiation study specific activity/procedure . 4 . Others define protocol 1 . Not able/willing comply study protocol procedure . 2 . Currently enrol clinical study another investigational drug device . 3 . Others define protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>